within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP08_Sofosbuvir;

model Sofosbuvir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 1.9722222222222224e-05,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.127,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008,
    Tlag = 10.200000000000001,
    Vdp = 0.067,
    k12 = 6.555555555555556e-05,
    k21 = 6.555555555555556e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Sofosbuvir</td></tr><tr><td>ATC code:</td><td>J05AP08</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>127</td><td>L</td></tr>
    <tr><td>clearance:</td><td>71</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus (HCV) NS5B polymerase. It is an antiviral drug used in combination with other direct-acting antivirals for the treatment of chronic hepatitis C infection. It is approved and widely used as part of combination therapies (e.g., with ledipasvir, velpatasvir, or daclatasvir) and has become a key component in HCV treatment regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Li, X, et al., &amp; Ding, Y (2018). Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects. <i>Clinical therapeutics</i> 40(9) 1556–1566. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2018.07.018\">10.1016/j.clinthera.2018.07.018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30185395/\">https://pubmed.ncbi.nlm.nih.gov/30185395</a></p></li><li><p>Panjasawatwong, N, et al., &amp; Cressey, TR (2024). Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment. <i>Antimicrobial agents and chemotherapy</i> 68(7) e0000824–None. DOI:<a href=\"https://doi.org/10.1128/aac.00008-24\">10.1128/aac.00008-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38767383/\">https://pubmed.ncbi.nlm.nih.gov/38767383</a></p></li><li><p>Jonas, MM, et al., &amp; Schwarz, KB (2024). Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. <i>Journal of pediatric gastroenterology and nutrition</i> 78(6) 1342–1354. DOI:<a href=\"https://doi.org/10.1002/jpn3.12045\">10.1002/jpn3.12045</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38644678/\">https://pubmed.ncbi.nlm.nih.gov/38644678</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AP08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Sofosbuvir;
